GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6491 Rauwolscine hydrochlorideSummary: α2-adrenergic antagonist -
B5623 S 32212 hydrochlorideSummary: inverse agonist of 5-HT2C receptors -
B6490 Cirazoline hydrochlorideSummary: α1 agonist -
B5617 DV 7028 hydrochlorideSummary: 5-HT2A receptor antagonist -
B6470 Agmatine sulfateSummary: α2-adrenergic receptor ligand -
B5610 EMD 281014 hydrochlorideSummary: 5-HT2A antagonist -
B6466 (S)-(-)-Propranolol hydrochlorideSummary: A β-adrenoceptor antagonist -
B5609 AT 1015Summary: Long-acting 5-HT2A antagonist -
B6464 ICI 89406Summary: β-adrenergic antagonist -
B5540 MS 245 oxalateSummary: 5-HT6 antagonist
